Increased Plasma Pyruvate Kinase M2 (PK‐M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications

• Published in: Journal of the American Heart Association Vol. 14; no. 2; p. e036170
• Main Authors: Cao, Lu, Dong, Xiaoyu, Chen, Fuzhong, Li, Guangjuan, Fang, Jiale, Han, Zhijun, Wang, Junhong
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 21.01.2025; Wiley
• Subjects: Aged; biomarker; Biomarkers - blood; Case-Control Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; heart failure; Heart Failure - blood; Heart Failure - diagnosis; Heart Failure - enzymology; Heart Failure - mortality; Heart Failure - physiopathology; Humans; Male; Middle Aged; Natriuretic Peptide, Brain - blood; Original Research; Patient Readmission; Peptide Fragments; Predictive Value of Tests; Prognosis; Prospective Studies; Pyruvate Kinase - blood; pyruvate kinase M2; Risk Factors; Severity of Illness Index; short‐term prognosis; Stroke Volume; Time Factors; Up-Regulation; Ventricular Function, Left; short‐term prognosis; heart failure; biomarker; pyruvate kinase M2

The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK-M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in patients with heart failure (HF). We conducted a prospective investigation involving 222 patients wi...